Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SenesTech Signs One Year Sales Agreement for ContraPest With an Arizona Brewpub

SenesTech
Posted on: 10 Aug 17

FLAGSTAFF, Ariz., Aug. 8, 2017 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today its latest sales agreement with an Arizona brewpub. The project will utilize ContraPest, SenesTech's proprietary technology for managing rodent pest populations through fertility control, for which the customer has agreed to an initial twelve month purchase agreement.

"Rodent control is a constant challenge in the restaurant industry despite all efforts at hygiene and cleanliness. As history has shown us rats are persistent and successful in their search for food sources. At the same time, restaurants have a "zero" tolerance for rodent dispersed poison. This makes it challenging for them to consider the commonly available solid rodenticides, which is why ContraPest is such a good choice. ContraPest provides a sustainable solution that is safe in reducing the invading populations," said SenesTech's co-founder and CEO, Dr. Loretta Mayer. "We look forward to working with this first customer in this segment in Arizona."

About SenesTech

SenesTech developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach. The company's first fertility control product, ContraPest, is marketed for use in controlling rat infestations. ContraPest's novel technology targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formula that promotes sustained consumption by rodent communities. The liquid is biodegradable, designed to be safe for handlers and non-target species such as wildlife, livestock and pets. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.

SenesTech's non-lethal approach of targeting reproduction is more humane, environmentally safe, and more effective in providing a sustainable solution to pest management. Currently no other non-lethal fertility control product is approved by the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA), for the management of rodent populations. SenesTech believes ContraPest will establish a new paradigm over rodenticides, without the negative environmental effects.  For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:  

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 10/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.